ALK and non-small cell lung carcinoma: The primary aim of this systematic review and NMA was to compare the safety and efficacy of lorlatinib and alectinib in patients with ALK-p ALK-inhibitor-naïve and advanced NSCLC (in the overall group of participants and in subgroups comprising Asian and non-Asian patients).